Lung Cancer

FDA Expands Indications for Pembrolizumab to Include Metastatic SCLC With Disease Progression on or After Other Therapies

On June 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the anti–programmed cell death protein 1 (PD-1) therapy pembrolizumab...

Breast Cancer

3-Year Outcomes in the KRISTINE Trial on Neoadjuvant Trastuzumab Emtansine Plus Pertuzumab in HER2-Positive Breast Cancer

As reported at the 2019 ASCO Annual Meeting and in the Journal of Clinical Oncology by Hurvitz et al, 3-year outcomes in the phase III KRISTINE trial...

Multiple Myeloma

MAIA Trial: Addition of Daratumumab to Lenalidomide/Dexamethasone in Untreated Myeloma Ineligible for ASCT

In the phase III MAIA trial reported in The New England Journal of Medicine, Facon et al found that the addition of daratumumab to lenalidomide/dexamethasone...


QuANTUM-R: Quizartinib vs Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD–Positive AML

In the phase III QuANTUM-R trial reported in The Lancet Oncology, Cortes et al found that the FLT3 inhibitor quizartinib produced a modest but significant improvement in overall survival...

Hematologic Malignancies
Multiple Myeloma

Selected Abstracts From the 2019 ASCO Annual Meeting: Plasma Cell Dyscrasias

To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens...


More Top Stories

Bladder Cancer

Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy

New Data on Improving Access to Cancer Care, Advances in Precision Medicine Highlighted at 2019 ASCO Annual Meeting

As this special edition of The ASCO Post goes to press, more than 32,000 cancer experts from around the world have convened in Chicago to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in...


EHA 2019: BELLINI Trial Evaluates Addition of Venetoclax to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma

The phase III BELLINI trial—reported by Kumar et al at the 24th Annual Congress of the European Hematology Association (EHA; Abstract LB2601) investigated the efficacy and safety of venetoclax/bortezomib/dexamethasone vs bortezomib/dexamethasone in patients with relapsed or refractory...

CNS Cancers

Manmeet S. Ahluwalia, MD, on Glioblastoma: Novel Cancer Vaccine With Standard Therapy

Richard T. Silver, MD, Receives 2019 ELN Merit Award

Richard T. Silver, MD, Professor of Medicine of the Division of Hematology and Medical Oncology and Emeritus Director of the Myeloproliferative Neoplasms Center at Weill Cornell Medicine, has been awarded the 2019 European -LeukemiaNet (ELN) Merit Award in recognition of his contributions to the...

Issues in Oncology

How Have We Got It So Wrong?

The past 20 years have seen an unprecedented increase in the development of effective drugs for the management of cancer. The advent of immunotherapy offers even the promise of cure for some previously highly resistant diseases. The science is brilliant, the need is ever increasing—but the cost...

Dose De-escalation in Adjuvant Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II study reported in the Journal of Clinical Oncology, Ma et al found that aggressive radiotherapy dose de-escalation in adjuvant chemoradiotherapy for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma was associated with disease control rates comparable to...

Prostate Cancer

Kim N. Chi, MD, on Castration-Resistant Prostate Cancer: Cabazitaxel vs Abiraterone or Enzalutamide in the Metastatic Setting

Northern New England Clinical Oncology Society Supports 2019 International Development and Education Award and Merit Awards

The Northern New England Clinical Oncology Society (NNECOS) is a tristate regional affiliate of ASCO serving oncology practices within Maine, New Hampshire, and Vermont. A long-time supporter of Conquer Cancer®, the ASCO Foundation, and its Young Investigator Award (YIA) program, NNECOS expanded...


Cediranib in Alveolar Soft-Part Sarcoma

In the phase II CASPS trial reported in The Lancet Oncology, Judson et al found evidence of activity of cediranib in alveolar soft-part sarcoma. In the double-blind trial, 48 patients from 12 sites in the United Kingdom, Spain, and Australia were randomly assigned 2:1 between July 2011 and July...